Medpace Holdings, Inc. (MEDP)

NASDAQ: MEDP · USD

$691

+17.32 (+2.6%)· Recorded snapshot

Market cap	19.3B
Revenue (ttm)	2.8B
Net income (ttm)	517.8M
EPS (ttm)	$18.0
Shares out	28M
P/E (trailing)	38.3x
P/E (forward)	35.9x
Volume	253,342
Beta	1.18

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 2.8B
Net income (ttm): 517.8M
EPS (ttm): $18.0
P/E (trailing): 38.3x
P/E (forward): 35.9x
Market cap: 19.3B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Giữ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E35.9

P25 n/aP50 n/aP75 n/a

Trailing P/E38.3

P25 n/aP50 n/aP75 n/a

ROE117.9

P25 n/aP50 n/aP75 n/a

ROIC793.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All MEDP indicators

Market & fundamental data

Available fields

268

Groups with data

Currency

USD

Showing 268 of 268 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001668397
Company name	Medpace Holdings, Inc.
Country	United States
Country code	US
CUSIP number	58506Q109
Earnings date	2026-10-21
Earnings time	amc
Employees	6,500
Employees change	500
Employees growth	8.33%
Enterprise value	$18.8B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-09-30
First seen	2026-05-09
Fiscal year end	December
Founded	1992
Industry	Diagnostics & Research
IPO date	2016-08-11
Is primary listing	Yes
Is SPAC	No
ISIN number	US58506Q1094
Last 10-K release date	2026-02-10
Last earnings date	2026-10-21
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$19.3B
Market cap category	Large-Cap
Next earnings date	2027-02-08
Options	Yes
Price	$691.12
Price currency	USD
Sector	Healthcare
SIC code	8731
Stock price date	2026-10-28
Symbol	MEDP
U.S. state	Ohio
Website	https://www.medpace.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	38.31x
Average P/E ratio (10Y)	33.97x
Average P/E ratio (3Y)	30.9x
Average P/E ratio (5Y)	29.51x
Earnings yield	2.61%
EV/Earnings	35.85x
EV/EBIT	30.58x
EV/EBITDA	29.26x
EV/FCF	27.8x
EV/Sales	6.54x
FCF / EV yield	3.6%
FCF yield	3.5%
Forward EV/Sales	6.28x
Forward P/E	35.88x
Forward P/S	6.46x
Graham number	92.12019
Graham upside	-86.51%
Industry forward P/E	30.92x
Industry P/E	50.57x
Lynch fair value	$419.31
Lynch upside	-38.58%
P/(FCF - SBC) ratio	29.6x
P/(OCF - SBC) ratio	27.26x
P/B ratio	32.21x
P/E ratio	38.33x
P/FCF ratio	28.6x
P/OCF ratio	26.41x
P/S ratio	6.73x
PEG ratio	2.46x
Price/EBITDA ratio	30.1x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	21.39%
EBITDA margin	22.35%
Effective tax rate	17.41%
FCF margin	23.52%
Gross margin	72.24%
Operating margin	21.39%
Pretax margin	22.09%
Profit margin	18.24%
Profit per employee	$79,665
Profitable quarters	39
Profitable years	10
Revenue per employee	$436,675
ROA	18.71%
ROA (5Y)	12.99%
ROCE	75.28%
ROE	117.88%
ROE (5Y)	49.16%
ROIC	793.61%
ROIC (5Y)	87.79%
SBC / revenue	0.79%
Tax / revenue	3.85%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	25.93%
EPS growth (Q)	25.39%
EPS growth (QoQ)	13.88%
EPS growth 10Y	62.53%
EPS growth 3Y	28.32%
EPS growth 5Y	30.14%
EPS growth quarters	19
EPS growth years	10
FCF growth	-1.35%
FCF growth (Q)	-16.59%
FCF growth (QoQ)	42.24%
FCF growth 3Y	20.9%
FCF growth 5Y	19.76%
Gross profit growth	24.97%
Gross profit growth (Q)	7.94%
Gross profit growth 3Y	20.67%
Gross profit growth 5Y	24.7%
Net income growth	19.59%
Net income growth (Q)	23.69%
Net income growth (QoQ)	13.26%
Net income growth 3Y	23.79%
Net income growth 5Y	23.25%
Net income growth quarters	19
Net income growth years	10
OCF growth	1.66%
OCF growth (Q)	-12.03%
OCF growth (QoQ)	33.69%
OCF growth 10Y	23.01%
OCF growth 3Y	20.46%
OCF growth 5Y	19.4%
Operating income growth	19.74%
Operating income growth (Q)	16.74%
Operating income growth 3Y	23.04%
Operating income growth 5Y	25.02%
Revenue growth	20.35%
Revenue growth (Q)	8.5%
Revenue growth (QoQ)	1.23%
Revenue growth 10Y	22.9%
Revenue growth 3Y	16.8%
Revenue growth 5Y	21.02%
Revenue growth quarters	25
Revenue growth years	11

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-55.4M
Depreciation and amortization	$27.3M
EBIT	$607.1M
EBITDA	$634.5M
EPS	$18.03
FCF per share	$23.87
Financing cash flow	$-246.4M
Free cash flow	$667.6M
Free cash flow minus SBC	$645.1M
Gross profit	$2.1B
Income taxes	$109.2M
Investing cash flow	$-55.2M
Net cash flow	$420M
Net income	$517.8M
Operating cash flow minus SBC	$700.6M
Operating income	$607.1M
Revenue	$2.8B
Stock-based compensation	$22.5M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	7
Book value per share	$20.92
Debt / EBITDA	0.25
Debt / equity	0.29
Debt / FCF	0.26
Goodwill	$662.4M
Long-term assets	$1.1B
Long-term liabilities	$221.6M
Net cash (debt)	$533.9M
Net cash / market cap	2.8%
Net cash growth	277.61%
Net debt / EBITDA	-0.84
Net debt / equity	-0.91
Net debt / FCF	-0.8
Piotroski F-Score	7
Property, plant and equipment	$327.6M
Shareholders' equity	$584.9M
Tangible book value	$-110.4M
Tangible book value per share	$-3.95
Total assets	$2.3B
Total cash	$705.3M
Total debt	$171.5M
Total liabilities	$1.7B
WACC	10.65%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	1.4
Current assets	$1.2B
Current liabilities	$1.5B
Current ratio	0.83
Net working capital	$-931M
Quick ratio	0.77
Working capital	$-251.1M
Working capital turnover	-7.12

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	5.07%
Dividend yield	0%
Shareholder yield	5.07%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	2,286.24%
10Y return CAGR	37.34%
10Y total return	2,286.24%
150-day SMA	$537.08
1D price change	2.57%
1M price change	10.81%
1M total return	10.81%
1W price change	10.18%
1W total return	10.18%
1Y price change	14.98%
1Y return CAGR	14.99%
1Y total return	14.98%
20-day SMA	$629.89
200-day SMA	$528.82
3M price change	16.36%
3M total return	16.36%
3Y price change	174.02%
3Y return CAGR	39.92%
3Y total return	174.02%
50-day SMA	$616.81
50-day SMA vs 200-day SMA	50over200
52-week high	$691.71
52-week high date	2026-10-28
52-week low	$373.00
52-week low date	2026-04-23
5Y price change	225.64%
5Y return CAGR	26.64%
5Y total return	225.64%
6M price change	62.76%
6M total return	62.76%
All-time high	$691.83
All-time high date	2026-10-28
All-time low	$21.76
All-time low date	2017-05-03
Average true range (ATR)	$20.87
Average volume	329.4K
Beta (1Y)	0.51
Beta (2Y)	0.98
Beta (5Y)	1.18
Change from 52-week high	-0.08%
Change from 52-week low	85.29%
Change from all-time high	-0.1%
Change from all-time low	3,051.68%
Change from open	0.2%
Day's gap	2.37%
Dollar volume	$175.1M
High price	$691.83
Low price	$679.92
Monthly RSI	70.42
Open price	$689.77
Position in 52-week range	94.04%
Premarket change	0.15%
Premarket close	$673.79
Premarket price	$674.80
Previous close	$673.79
Price vs 150-day SMA	27.69%
Price vs 20-day SMA	8.88%
Price vs 200-day SMA	29.69%
Price vs 50-day SMA	11.19%
Relative volume	0.77
RSI	70.84
Sharpe ratio	0.46
Sharpe ratio (3Y)	0.86
Sharpe ratio (5Y)	0.66
Sortino ratio	0.71
Sortino ratio (3Y)	1.65
Sortino ratio (5Y)	1.25
Volume	253.3K
Weekly RSI	70.52
YTD price change	22.11%
YTD total return	22.11%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	22.7M
Float percentage	81.2%
Shares change (QoQ)	-0.64%
Shares change (YoY)	-5.07%
Shares held by insiders	18.74%
Shares held by institutions	89.04%
Shares outstanding	28M
Short % of float	7.03%
Short % of shares	5.71%
Short ratio	6.6 days

Deeper analysis on MEDP

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this MEDP report

Is a complete MEDP research report available?

No complete published report is available for Medpace Holdings, Inc. (MEDP) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Medpace Holdings, Inc. (MEDP)

Price

Financial snapshot

Fair-value bridge

Latest news · MEDP

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All MEDP indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on MEDP

Frequently asked questions